کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5536363 | 1402286 | 2017 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes
ترجمه فارسی عنوان
شناسایی آنتی بادیهای مونوکلونال انسانی که خلایلی از سروتیپ های متعدد ویروس می شود
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
wpvmAbCPEOPVcVDPVIPVGPEIHuman immunityComplementary determining region 3CDR3amino acid - آمینو اسیدMonoclonal antibody - آنتی بادی مونوکلونالCytopathic effect - اثر سیتوپاتیکAFP - تست AFP یا آلفا فیتو پروتئینNeutralization - خنثی سازیCross-neutralization - خنثی سازی صلیبPolio eradication - ریشه کن سازی فلج اطفالimmunoglobulin light chain - زنجیره سبک ایمونوگلوبولینImmunoglobulin heavy chain - زنجیره سنگین ایمونوگلوبولینGlobal polio eradication initiative - طرح جهانی ریشه کنی فلج اطفالAcute flaccid paralysis - فلج ناگهانی حادinactivated polio vaccine - واکسن فلج اطفال غیر فعال شدهWild poliovirus - ویروس ویولون وحشیPoliovirus - پلیو ویروس
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
چکیده انگلیسی
Following the eradication of wild poliovirus (PV), achieving and maintaining a polio-free status will require eliminating potentially pathogenic PV strains derived from the oral attenuated vaccine. For this purpose, a combination of non-cross-resistant drugs, such as small molecules and neutralizing monoclonal antibodies (mAbs), may be ideal. We previously isolated chimpanzee and human mAbs capable of neutralizing multiple PV types (cross-neutralization). Here, we describe three additional human mAbs that neutralize types 1 and 2 PV and one mAb that neutralizes all three types. Most bind conformational epitopes and have unusually long heavy chain complementarity determining 3 domains (HC CDR3). We assessed the ability of the mAbs to neutralize A12 escape mutant PV strains, and found that the neutralizing activities of the mAbs were disrupted by different amino acid substitutions. Competitive binding studies further suggested that the specific mAb:PV interactions that enable cross-neutralization differ among mAbs and serotypes. All of the cloned mAbs bind PV in the vicinity of the “canyon”, a circular depression around the 5-fold axis of symmetry through which PV recognizes its cellular receptor. We were unable to generate escape mutants to two of the mAbs, suggesting that their epitopes are important for the PV life cycle. These data indicate that PV cross-neutralization involves binding to highly conserved structures within the canyon that binds to the cellular receptor. These may be facilitated by the long HC CDR3 domains, which may adopt alternative binding configurations. We propose that the human and chimpanzee mAbs described here could have potential as anti-PV therapeutics.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 35, Issue 41, 4 October 2017, Pages 5455-5462
Journal: Vaccine - Volume 35, Issue 41, 4 October 2017, Pages 5455-5462
نویسندگان
Rama Devudu Puligedda, Diana Kouiavskaia, Fetweh H. Al-Saleem, Chandana Devi Kattala, Usman Nabi, Hamid Yaqoob, V. Sandeep Bhagavathula, Rashmi Sharma, Konstantin Chumakov, Scott K. Dessain,